14 results about "AMPK" patented technology

Described herein are dosage forms comprising the compound:wherein the dosage form can be a solid dosage form, a liquid dosage form, or a solid amorphous dispersion.

This document provides methods and materials for increasing the level of phosphorylated AMPK. For example, compounds (e.g., organic compounds) having the ability to increase the level of phosphorylated AMPK within cells, formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for making formulations containing compounds having the ability to increase the level of phosphorylated AMPK within cells, methods for increasing the level of phosphorylated AMPK within cells, and methods for treating mammals (e.g., humans) having a condition responsive to an increase in the level of phosphorylated AMPK are provided.

Described herein are compounds of Formula I,wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or peripheral vascular disease.

Compounds having activity as modulators of AMPK are provided. The compounds have Structure (I), (II), (III), or (IV):or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R1a, R2, R3, W, X, Y, R4, R5, R6, X1, X2, X3, n, R8, R9, R10a, R10b, X4, ring A, R11, R12, R13a, R13b, and X5 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of AMPK are also provided.

This method and composition involves oral administration of a low dose of D-ribose to enhance adenosine monophosphate-activated protein kinase (AMPK) activity in both exercising and sedentary mammals, improve mitochondrial-related oxidative metabolic parameters, and thereby promote overall metabolic health in mammals.

The present disclosure relates to methods and compositions for editing an AMPK polynucleotide encoding an AMPK protein. The disclosure also relates to methods and compositions for modulating activity of an AMPK protein, for promoting activation of an AMPK protein, for repairing function of a pathogenic AMPK protein, and methods for regulating energy homeostasis and / or for treating or preventing an AMPK-associated disease or condition in a subject.

Disclosed are compounds or pharmaceutically acceptable salts thereof according to formulae IA, IB, or IC as well as pharmaceutical compositions, and methods of use thereof: Formula (IA), (IB), (IC), wherein moieties A and B are further described herein. In certain embodiments, a compound disclosed herein is a 5'-AMP-activated protein kinase ('AMPK') agonist.

The application belongs to the technical field of bioactive peptides, and discloses application of a polypeptide in regulating lipid metabolism. The polypeptide is IPIQY, and the amino acid sequence is shown as SEQ ID NO. 1. The polypeptide directly acts on hepatocytes to activate AMPK. The application first discloses that the polypeptide IPIQY can directly act on hepatocytes to activate the AMPK signal pathway, and thus realizes reduction of the content of triglyceride in hepatocytes and reduction of lipid accumulation.

The present invention relates to synergistic composition for delaying cellular senescence. Particularly, the present invention relates to the bioactive composition for activation of the AMPK-FOXO3a signaling pathway, wherein the composition comprising synergistic combination of FOXO3a promoter and AMPK activators and in specific concentration that controls cell senescence, apoptosis, and autophagy, lire present synergistic composition is useful in controlling vascular ageing disorders.

This invention discloses the application of NT5C1A as a therapeutic target for myocardial ischemia-reperfusion injury, belonging to the field of biomedical technology. Through proteomics screening and in vitro and in vivo experiments, this invention is the first to discover and demonstrate that NT5C1A is upregulated in the pathological process of MIRI, and is a key upstream factor regulating the AMPK / SIRT1 / PGC-1α signaling pathway. Overexpression of NT5C1A can effectively activate this pathway, synergistically regulating multiple downstream pathological processes: promoting the expression of mitochondrial fusion proteins Mfn-2 and OPA1, inhibiting the expression of the splitting protein DRP1; significantly promoting ATP production and improving energy metabolism disorders; and regulating the balance of apoptosis-related protein Bax / Bcl-2 expression, inhibiting cardiomyocyte apoptosis, ultimately reducing myocardial damage, improving myocardial function, and reducing the infarct area. This invention provides a new target and strategy for the precise intervention of MIRI.

The invention discloses a novel application of an AMPK (adenosine monophosphate kinase) activator Aldometanib in preparation of a medicine for inhibiting inflammatory pain. The research finds that animal experiments prove that the AMPK activator Aldometanib can obviously activate p-AMPK, effectively relieve inflammatory pain, improve the pain threshold value and relieve inflammation, and is high in safety, wide in application range and free of obvious side effects. The invention also discloses a molecular mechanism of the Aldometanib for relieving pain, and finds that the Aldometanib reduces the expression of pro-inflammatory cytokines such as TNF-alpha, IL-1beta, IL-6, IL-8 and the like by activating p-AMPK and regulating an STAT3-BDNF-TrkB pathway, and also reduces the activation of microglial cells, thereby reducing the damage and sensitization of nerve cells and playing a role in easing pain. The application of the Aldometanib in the field of medicine is expanded, a safe and effective treatment strategy is provided for treatment of inflammatory pain, and the application has wide clinical application prospects and market value.

Disclosed are activators of the phosphatase PHLPP1 (PH domain and Leucine rich repeat protein phosphatase 1), a widely conserved enzyme involved in the regulation of two signaling networks, mTOR and AMPK, the balance and coordination of which controls the cellular response to either ample or restricted fuel supply to cells. These activators are referred to as SNAP (Snail-derived Activators of PHLPP) compounds as they are based on the structure of a Dormancy Inducing factor (DIF) discovered in hibernating snails. SNAP compounds are demonstrated to increase the activity of both human recombinant PHLPP, and mouse PHLPP1. One such example of a SNAP compound is 3-(2-methyl-8- (2-((oxidanidylsulfonyl)oxy) ethyl)-3,4-dihydro-2H-chromen-2-yl) propanoate-pyridine.

Compounds having activity as modulators of AMPK are provided. The compounds have Structure (I), (II), (III), or (IV): (I) (II) (III) (IV) or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R1a, R2, R3, W, X, Y, R4, R5, R6, X1, X2, X3, n, R8, R9, R10a, R10b, X4, ring A, R11, R12, R13a, R13b, and X5 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of AMPK are also provided.

The present invention relates to adenine which is useful to activate AMP-activated protein kinase (AMPK) and the use of adenine in the prevention or treatment of conditions or disease and thereby prevent or treat conditions or diseases which can be ameliorated by AMPK in a mammal.